Patients appear sicker than with more common viral illnesses
ed from other countries and their subsequent transmission to unvaccinated people. From 2001 to 2012, a median of four outbreaks and 60 cases were reported annually to the US Centers for Disease Control and Prevention. 4 In January 2015, a multistate measles outbreak originating in Disneyland in California was recognized. As of April 17, when the outbreak was declared over, 111 measles cases from seven states had been linked to this outbreak. 5 Of the evaluable cases, 44% were in unvaccinated people and 38% were in those whose vaccination status was unknown or undocumented. The median age of patients was 21, and 20% required hospitalization.
This outbreak, as well as four other smaller US outbreaks the same year, underscores the transmissibility of the virus in populations containing only a small percentage of unvaccinated people. 6 
■ DISTINCTIVE CLINICAL PICTURE
The incubation period for measles infection is 7 to 21 days, with most cases becoming apparent 10 to 12 days after exposure. Measles should be suspected in a patient with the following clinical features whose history indicates susceptibility and exposure (ie, an unimmunized person with a history of exposure or travel):
Severe acute respiratory illness. Measles usually presents as an acute respiratory viral illness, which typically lasts 2 to 4 days. The illness involves high fevers, malaise, anorexia, and the "three Cs": cough, coryza (rhinitis), and conjunctivitis. Patients usually appear sicker than those with more common viral illnesses.
Koplik spots, which are pathognomonic for measles, are seen in the fi rst few days of illness. They are bluish-white, slightly raised lesions on an erythematous base on the buccal mucosa, usually opposite the fi rst molar ( Figure  1) . Spots can also be seen on the soft palate, conjunctiva, and vaginal mucosa. Koplik spots usually disappear after a few days and often are not appreciable at the time of evaluation.
Discrete erythematous patches develop on the face and neck a day after the appearance of Koplik spots. This rash becomes more confl uent as it spreads to involve the entire body ( Figure  2) . It typically lasts for 3 to 7 days, then fades in a similar pattern. The confl uent nature of this rash and its spread from the face and neck to the entire body are characteristic of measles. Patients are highly contagious from 4 days before the onset of the rash to 4 days after.
■ COMPLICATIONS CAN BE SEVERE
Those at highest risk for measles complications are infants, children under age 5, adults over age 20, pregnant women, and immunosuppressed individuals. Pneumonia-either a primary measles pneumonia or a secondary viral or bacterial pneumonia-is the most common cause of death. 8, 9 Viruses complicating measles are typically adenovirus and herpes simplex virus. Bacteria causing secondary infection are usually Staphylococcus aureus and Streptococcus pneumoniae and, less commonly, gram-negative bacteria.
Laryngotracheobronchitis (croup) is the second most common cause of death, with bacteria and viruses similar to those causing measles-related pneumonia.
Otitis media is the most common complication of measles. Other respiratory complications include mastoiditis, pneumothorax, and mediastinal emphysema.
Acute measles encephalitis occurs in 1 measles case per 1,000 and often results in permanent brain damage. During the convalescent phase of the illness, fever again emerges, FIGURE 1. Koplik spots (arrow), indicating the onset of measles, in a patient who presented 3 days before the eruption of skin rash.
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with the development of headaches, seizures, and altered consciousness.
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Subacute sclerosing panencephalitis is a rare fatal degenerative disease of the central nervous system caused by a persistent infection with a defective measles virus. The precise pathophysiology is unclear, but it is thought that mutations of the viral genome lead to altered cellular immunity. 11 The condition typically occurs 7 to 10 years after the initial measles infection, particularly in those who developed measles before age 2. Clinical manifestations include behavioral disturbances, intellectual deterioration, and myoclonic seizures, slowly progressing to a vegetative state and death. 12 Other complications of measles include diarrhea and stomatitis, which are associated with malnutrition in developing countries, and subclinical hepatitis, thrombocytopenia, appendicitis, ileocolitis, hypokalemia, and myocarditis.
During pregnancy, measles infection can be complicated by primary measles pneumonia and is associated with an increased risk of miscarriage and premature birth.
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Patients with a cell-mediated immunodefi ciency who develop measles are particularly susceptible to fatal measles pneumonia and acute progressive encephalitis. 14 
■ ATYPICAL MEASLES IN THOSE WHO RECEIVED KILLED VACCINE
From 1963 to 1967, a killed measles vaccine was available in the United States. Those who received this vaccine are susceptible to an atypical form of measles when exposed to the virus, 15 characterized by a 1-to 2-day prodrome, followed by the appearance of a maculopapular or petechial rash on the distal extremities that spreads centripetally. Patients develop high fever and edema of the hands and feet, and have a more prolonged course than with classic measles. It is believed not to be contagious. 16 
■ LABORATORY CONFIRMATION
Laboratory confi rmation of measles is recommended for suspected cases. Because viral isolation is technically diffi cult and is not readily available in most laboratories, measles-specifi c immunoglobulin M antibody serologic testing is most commonly used. It is almost 100% sensitive when done 2 to 3 days after the onset of the rash. 17 Measles RNA testing by real-time polymerase chain reaction to detect measles virus in the blood, throat, or urine is more specifi c and if available may be preferred over serologic testing. 18 
■ SUPPORTIVE MANAGEMENT AND VITAMIN A SUPPLEMENTATION
No specifi c antiviral therapy for measles is available. Management involves supportive measures and monitoring for secondary bacterial complications. The World Health Organization and the American Academy of Pediatrics recommend vitamin A supplementation for all children with acute measles. 19 In developing countries, it has been shown to reduce rates of morbidity and death in measles-infected children. 20 In the United States, children with measles have been found to have low serum levels of vitamin A, with lower levels associated with more severe disease. 
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Vitamin A supplementation is recommended for acute measles All school-age children who received only one dose of measles vaccine should receive the second dose
■ VACCINATION RECOMMENDATIONS
The only measles vaccine available in the United States is a live further-attenuated strain prepared in chick embryo cell culture and combined with mumps and rubella vaccine (MMR) or with measles, mumps, rubella, and varicella vaccine (MMRV).
Healthy children. Two doses of measles vaccine are recommended, as a single dose is associated with a 5% failure rate. The recommended schedule is:
• First dose at age 12 to 15 months • Second dose at the time of school entry (ages 4 to 6), or at any time at least 28 days after the fi rst dose. 19 More than 99% of children who receive two doses of vaccine according to this schedule develop serologic evidence of measles immunity. Vaccination provides long-term immunity, and many epidemiologic studies have documented that waning immunity after vaccination occurs only very rarely. 21 All school-age children, including elementary, middle, and high school students, who received only one dose of measles vaccine should receive the second dose.
Adults born in 1957 or later should receive at least one dose of measles vaccine unless they have other acceptable evidence of immunity, such as: 4 • Documentation of age-appropriate live measles vaccine, ie, one dose of vaccine for adults not at high risk, or two doses for those at high risk (see below) • Laboratory evidence of immunity (ie, measles immunoglobulin G in serum) • Laboratory confi rmation of disease.
Adults born before 1957 can be considered to be immune to measles, although MMR vaccine can be administered in those without contraindications.
Adults at increased risk of exposure or transmission of measles and who do not have evidence of immunity should receive two doses of MMR vaccine, given at least 28 days apart. This high-risk group includes:
• Students attending college or other posthigh school educational institution • Healthcare personnel • International travelers.
During measles outbreaks, every effort should be made to ensure that those at high risk are vaccinated with two doses of MMR or have other acceptable evidence of immunity.
■ LIVE VACCINE IS SAFE FOR MOST PEOPLE
Mild side effects. A transient fever, which may be accompanied by a discrete or confl uent rash, occurs in 5% to 15% of recipients 5 to 12 days after vaccination. Transmission does not occur. People who have been newly vaccinated do not transmit the virus to susceptible contacts, even if they develop a vaccine-associated rash. The vaccine can safely be given to close contacts of immunocompromised and other susceptible people.
Egg allergy not a concern. Measles vaccine is produced in chick embryo cell culture but has been shown to be safe for people with egg allergy and is recommended without the need for egg allergy testing. 
MEASLES ■ INFECTION CONTROL AND PREVENTION
Healthcare workers should maintain a high index of suspicion for measles and implement isolation procedures promptly in patients with a febrile illness, rash, and a history of travel abroad or contact with travelers from abroad. 23 Suspected cases should be reported promptly to local health agencies to help limit spread.
Patients with measles should be placed in airborne isolation (eg, use of an N95 or higher level respirator and an airborne infection isolation room) for 4 days after the onset of the rash in a normal host and for the duration of the illness in an immunocompromised patient. Healthcare staff, regardless of their immunity status, should adhere to these precautions when entering the room of infected patients.
Immunization programs should be established to ensure that everyone who works or volunteers in healthcare facilities is protected against measles. 4 Postexposure prophylaxis. Measles vaccination given to susceptible contacts within 72 hours of exposure may provide protection against infection and induces protection against subsequent measles exposures. 24, 25 Vaccination is the best intervention for susceptible contacts older than 12 months who do not have a contraindication to measles vaccination, and for those who have received only one dose of measles vaccine.
Passive immunization. Active immunization is the best strategy for controlling measles outbreaks. Passive immunization with intramuscularly or intravenously administered immunoglobulin given within 6 days of exposure can be used to prevent transmission or modify the clinical course of infection for susceptible contacts at high risk of developing severe or fatal measles. This includes people who are being treated with immunosuppressive agents, HIVinfected, pregnant, or younger than 1 year of age. 
